129321-60-4

Basic information

• Product Name: 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane
• Synonyms: 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane;{[2-(cyclopropylMethoxy)ethoxy]Methyl}(propyl)aMine
• CAS NO: 129321-60-4
• Molecular Formula: C₈H₁₃NO₂
• Molecular Weight: 155.2
• Mol File: 129321-60-4.mol

Chemical Properties

• Boiling Point: 258.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.10±0.20(Predicted)
• CAS DataBase Reference: 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane(CAS DataBase Reference)
• NIST Chemistry Reference: 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane(129321-60-4)
• EPA Substance Registry System: 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane(129321-60-4)

Safety Data

• Hazardous Substances Data: 129321-60-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,8-Dioxa-10-azadispiro[2.0.4.3]undecane is used as a potential pharmaceutical agent due to its unique structure and possible biological activity. Its heterocyclic nature may contribute to the development of new drugs with novel mechanisms of action.
Used in Organic Synthesis:
In the field of organic synthesis, 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane serves as a valuable building block for the assembly of more complex molecules. Its spirocyclic framework can be a key component in the synthesis of advanced organic compounds with specific properties and applications.
However, it is important to note that the complex structure of 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane may pose challenges in terms of synthesis and handling. Specialized expertise and careful precautions are required to manipulate 5,8-Dioxa-10-azadispiro[2.0.4.3]undecane effectively, particularly in a laboratory or industrial setting.

Upstream product

• 147011-43-6 5-benzyl-7,7-ethylenedioxy-5-azaspiro[2.4]heptane 

Downstream Products

• 1160861-29-9 C₁₄H₁₅FN₂O₄ 
• 1214265-35-6 3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)-nitrobenzene 
• 1214265-36-7 C₁₄H₁₆F₂N₂O₂ 
• 1214265-28-7 (S)-N-{{3-[3,5-difluoro-4-(7-fluoro-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-27-6 (S)-N-{{3-[3,5-difluoro-4-(7-hydroxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-42-5 (S)-N-{{3-[3,5-difluoro-4-(7-oxo-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-38-9 (R)-{N-3-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methanol 
• 1214265-37-8 N-carbobenzyloxy-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]aniline 
• 1214265-34-5 (S)-N-{{3-[3,5-difluoro-4-(7-amino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-40-3 (R)-{N-3-[3,5-difluoro-4-(7,7-ethylenedioxy-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl azide 
• 1214265-44-7 C₁₈H₂₀F₂N₆O₃ 
• 1214265-29-8 (S)-N-{{3-[3,5-difluoro-4-(7-hydroxyimino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-31-2 (S)-N-{{3-[3,5-difluoro-4-(7-hydrazino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 
• 1214265-30-1 (S)-N-{{3-[3,5-difluoro-4-(7-methoxyimino-5-azaspiro[2,4]heptan-5-yl)phenyl]-2-oxo-5-oxazolidinyl}methyl}acetamide 

Relevant articles and documents

Synthesis and antibacterial activities of novel oxazolidinones having spiro[2,4]heptane moieties

The synthesis of a new series of oxazolidinones having spiro[2,4]heptane moieties is described. Their in vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of substituents on the oxazolidinone ring was investigated. A particular compound Ih having fluoro group showed the most potent antibacterial activity.

Spiro compounds and methods of use

The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with protein tyrosine kinases, especially epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), to their method of use as medicaments and to their method of use in the manufacture of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans.

Spiro compound

The present invention relates to spiro compounds of general formula I: STR1 wherein the substituents are herein below defined. The present invention relates to antibacterial spiro compounds which are of value as drugs for humans, veterinary drugs or drugs for use in fish culture or as preservatives, and to antibacterial compositions containing one or more of the same compounds as active ingredients.